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Abstract  
 
 
BACKGROUND & AIMS: Most patients with esophageal adenocarcinoma (EAC) present de 
novo.   Although this may be due to inadequate screening strategies, the precise reason for 
this observation is not clear..   We compared survival of patients with prevalent EAC with 
and without synchronous BE/intestinal metaplasia of the esophagus (IM) at the time of 
EAC diagnosis. 
METHODS: Clinical data were studied using Cox Proportional Hazards regression to 
evaluate the effect of synchronous BE/IM on EAC survival independent of age, sex, TNM 
stage and tumor location. Two cohorts from the Mayo Clinic and a U.K. 
multicenter prospective cohort were included.  
RESULTS:  The Mayo cohort had 411 EAC patients with 49.3% with BE/IM demonstrating 
a survival benefit as compared to those without (hazard ratio (HR), 0.44; 95% CI: 0.34 – 
0.57, P<0.001). In a multivariable analysis BE/IM was associated with better survival 
independent of age, sex, stage and tumor location and length (adjusted HR: 0.66, 95% CI: 
0.5–0.88, P=0.005). The UK cohort contained 1417 patients, 45% with BE/IM 
demonstrating a survival benefit as compared with non-BE/IM patients (HR 0.59, 95% CI: 
0.5-0.69, P<0.001) with continued significance in multivariable analysis that included age, 
sex, stage, and tumor location (adjusted HR 0.77, 95% CI: 0.64-0.93, P=0.006). 
CONCLUSION:  Two types of esophageal adenocarcinoma can be characterized based on 
the presence or absence of Barrett’s epithelium.  These findings have implications for 
understanding the etiology of EAC and determining prognosis as well as for development of 
optimal clinical strategies to identify patients at risk. 
Key words: Esophageal adenocarcinoma, Barrett’s esophagus, Survival, Esophagus 
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BACKGROUND 
     Esophageal adenocarcinoma (EAC) is a major public health concern due to rapidly increasing 
incidence rates and with fewer than 20% patients surviving beyond five years. One of the most well 
defined risk factors is the presence of the precursor lesion Barrett’s Esophagus (BE) which may occur on 
the background of heartburn symptoms or remain clinically silent. There has therefore been a concerted 
effort over several decades to identify and monitor patients with BE characterized by intestinal 
metaplasia
1
. However, the overwhelming majority of patients who develop EAC present de novo
2
 and 
therefore do not benefit from endoscopic surveillance programs
3-5
. Research efforts have therefore 
focused on finding easily identifiable factors that might select an at risk group for more systematic 
screening 
6-10
.  Similarly, researchers have been developing less expensive and easier to use screening 
devices and biomarker assays applied to biopsies, cytology specimens and blood samples 
11, 12
, 
13
. 
    It has been assumed that the reflux-induced, inflammation to cancer sequence is similar across all 
patients who develop EAC such that identification of BE would give us years of surveillance to treat 
incident dysplasia or cancer before the development of incurable adenocarcinoma.  However, in some 
patients who develop EAC it has been observed that no Barrett’s is present at the time of surgical 
resection 
14
.  In these patients, it is assumed that the cancer grows over and/or replaces the previously 
extant metaplasia.  
    However, another quite distinct explanation could be possible.  If a more rapidly evolving and/or 
aggressive form of EAC developed from a small and easily missed area of esophageal metaplastic 
epithelium, or if the stage of intestinalization between inflammation and cancer was more ephemeral , 
less prominent or absent
14,15, 25
  attenuating identification with our current screening strategies, then a 
large proportion of prevalent EAC could be explained.  In keeping with this there is some molecular 
evidence that catastrophic genomic events such as chromothripsis could conceivably lead to more rapid 
progression to cancer15, 16.   
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We thus hypothesized that there might be a group of patients with EAC without co-existing 
Barrett’s Esophagus/IM (non- BE/IM) at the time of cancer diagnosis who have a more aggressive form 
of EAC which might lead to a poorer prognosis when compared to those with prevalent Barrett’s 
Esophagus/IM (BE/IM). To address this question we compared the clinico-pathological characteristics 
and survival in two types of patients: those who present with EAC in the context of histologic and/or 
endoscopically identifiable IM of the esophagus to those who present with adenocarcinoma without 
identifiable intestinal metaplasia (non-BE/IM).  This question was evaluated in two distinct but 
contemporaneous cohorts for whom we had high quality pathological and outcome data available. 
 
METHODS 
Study population  
Two cohorts were independently collected and analyzed. At the Mayo Clinic, Rochester all patients with 
a diagnosis of EAC treated in the years 2011-2012 were included regardless of the stage and treatment 
modality and a retrospective analysis was conducted. These years were selected to allow us to estimate 
5 years mortality. The study was approved by the Mayo Clinic Institutional Review Board (IRB: 17-
003675 on 5/15/2017). A prospective multicenter cohort was studied from the UK Oesophageal Cancer 
Clinical and Molecular Stratification (OCCAMS). The UK based consortium was set-up in 2010 in order to 
prospectively collect clinical and molecular data to inform patient management strategies and as the 
vehicle for whole-genome sequencing data as part of the International Cancer Genome Consortium. The 
study was registered (UKCRNID 8880) and approved by the relevant institutional ethics committees (REC 
07/H0305/52 and 10/H0305/1) and all subjects provided individual informed consent. This analysis 
included all OCCAMS patients diagnosed with EAC from 2002-2017 from 25 sites across the UK, all 
stages of disease, all treatment modalities, and all locations as reported by Siewert classifications 17, and 
follow-up for all patients is up to 5 years.  
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Although these two cohorts were studied independently, the following common methodology was 
employed.  Patients were excluded for the following reasons: esophageal squamous cell carcinoma 
(Mayo n=75, OCCAMS n=122), non-primary esophageal cancer (Mayo n=17, OCCAMS n=37), and 
absence of pathology specimens (Mayo n=12). For this study we are interested in all EAC cases 
presenting outside of Barrett’s surveillance programs, because surveillance detected cases are likely to 
be biased by being earlier stage. Patients with EAC detected in a surveillance program more than one 
year after identification of Barrett’s esophagus were excluded from the Mayo cohort (n=97). The 
OCCAMS cohort includes 135 patients who self-reported being in surveillance for Barrett’s as there was 
no information regarding the timeline for Barrett’s diagnosis and subsequent surveillance. These are 
evaluated for their effect on survival in the results section.  All patients had BE/IM at the time of their 
cancer diagnosis. 
 
Pathology Review 
A strict expert pathology review was performed by one specialized gastrointestinal pathologist with over 
30 years of experience in the Mayo clinic Cohort (T.C.S). In the OCCAMS cohort pathology was reviewed 
by two or more pathologists for all cases: the upper-gastrointestinal pathologist at the referring hospital 
followed by review performed by the OCCAMS central study upper-GI pathologist with over 20 years of 
experience.  The pathology reviews were abstracted from prior interpretation. 
The T, N, M cancer stage were assigned in both cohorts according to the American Joint Committee on 
Cancer (AJCC) 7th edition
18
 using the available information in the medical record including clinical notes, 
endoscopic ultrasound (EUS), positron emission tomography (PET), endoscopic mucosal resection (EMR) 
and histopathological evaluation following surgical resection. In patients who underwent neoadjuvant 
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therapy prior to surgical resection, the most advanced stage identified either prior to treatment or at 
the time of surgical resection was used.  
 
Barrett’s esophagus was defined by visual changes identified endoscopically in the pre-staging 
evaluation together with pathology demonstrating IM at time of surgical resection when reviewed by 
expert GI pathologists in the recruiting hospitals. IM was also identified in cases without macroscopic 
evidence of Barrett’s upon expert review of the pathology specimen. In a small group of patients who 
were treated with chemo-radiation therapy without endoscopic or surgical resection, BE/IM was 
ascertained using visual endoscopic appearance and endoscopic biopsies from the tumor.  
The reviewing pathologists followed a specific synoptic report proposed by the College of American 
Pathologists (www.cap.org/cancerprotocols) and the OCCAMS Consortium protocol in which both 
require the proximal and distal resection margins and tumor to be thoroughly evaluated for BE. In 
addition, extensive sampling is performed for all tumor borders of the resected esophagus/tumor and 
the tumor bed making sampling error less likely. The number of biopsies varied based on the tumor size.  
 
Statistical Analysis  
Baseline characteristics were compared between the two groups using chi-square χ
 2
 for categorical 
variables and student t-test for continuous ones. The primary outcome was overall survival.  Survival in 
the Mayo cohort was ascertained from the date of diagnosis to death or the date of data collection 
(administrative censoring), using online death records from U.S. Social Security Death Index. Survival 
time in the OCCAMS Consortium was evaluated from the date of diagnosis to the date the patient was 
last seen in clinic, or the date of death.  Survival was plotted using a Kaplan-Meier curve with statistical 
comparison between the two groups using the log-rank test. A Cox proportional hazard regression 
model was used to examine the impact of BE/IM on overall survival. Unadjusted and adjusted hazard 
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ratios were calculated adjusting for possible predefined confounders. In both cohorts age and sex were 
included.  
 
Predefined subgroup analyses were performed to examine if the survival effect of BE/IM was instead 
driven by the differential survival seen by stage, treatment, chemo-sensitivity, or due to the location of 
the tumor (i.e. IM being more likely to be involved due to cardia involvement). Each cohort was 
independently evaluated for these subgroups based on the specific data available.  Two sided P<0.05 
was considered statistically significant. A final multivariable model is evaluated in both cohorts that 
includes all significant subgroups, age, and sex. 
Missing value imputation was performed on the UK cohort to evaluate how these missing data may be 
influencing the survival effects. The missing values for variables (e.g. TNM stages, Siewert class, age at 
diagnosis, sex) were imputed using a multivariable chained equations method that applied random 
forest to categorical variables, and used the distribution means for continuous variables
19
. Imputation 
was performed for 20 iterations with the Cox multivariable regression model evaluated on each 
iteration. We report on the mean values of the Cox regression model iterations. The imputed data was 
not used when reporting the primary or final Cox regression analyses. No imputation was performed on 
the Mayo Cohort.  
All analysis on the Mayo cohort was performed using STATA 14.0 (College Station, Texas, USA). All 
analysis on the OCCAMS cohort was performed using R v3.4.3, with the packages ‘survival’ v2.41-3, 
‘coxme’ v2.2-7, ‘mice’ v.3.0.0, and ‘survminer’ v0.4. 
 
RESULTS 
Patient Characteristics 
Retrospective cohort Mayo Clinic 
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There were 411 patients with prevalent EAC treated in the Mayo Clinic during the years 2011 and 2012 
who met the inclusion criteria. 204 patients (49.3%) had evidence of associated IM with or without a 
macroscopically visible BE segment, leaving 207 with no associated IM. The mean age was 64.0 ± 10.7 
years (interquartile range IQR: 57 -72 years) without a meaningful clinical difference between the two 
groups (P=0.06). The cohort was male predominant 85.2% as expected for this disease. The BE/IM and 
non-BE/IM group were similar in terms of BMI, family history of esophageal cancer and smoking (P 
>0.05) (Table 1).  
 
Prospective Multicenter Cohort OCCAMS Consortium 
In the UK multi-center cohort, 1417 patients who had recorded information regarding BE status, stage, 
chemotherapy, and survival were included.  634 (45 %) had Barret’s adjacent to the tumor, while 783 
(55%) did not. The mean age was 66 ± 9.5 years (IQR: 60-73) without a meaningful clinical difference 
between the groups (P>0.05). The two groups were similar in male predominance (83%), history of 
smoking, and family history of EAC (P>0.05), though BE/IM patients had a slightly increased BMI 
(P<0.001) (Table 1). 
 
Lesion Features 
Mayo Clinic 
Most tumors (n=226, 55%) occurred at the distal esophagus (Siewert Type I) comprising 109 
(54.3%) in the BE/IM and 117 (56.5%) in the non-BE/IM group. 166 patients had Siewert Type II tumors 
spanning the EGJ with 86 patients (42.2%) in the BE/IM group and 80 patients (38.6%) in the non-BE/IM. 
2% of all the tumors were in the middle of the esophagus with the distal end of the tumor above 5 cm 
from EGJ.  
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Cancers were divided between stages with stage I (n=72, 17.5%), stage II (n= 92, 22.4%), stage III 
(n=154, 37.5%) and stage IV (n=93, 22.6%). Patients in the prevalent BE/IM group presented at earlier 
stages with 30.4% stage I, 27% stage II, 29.9% stage III and 12.7% stage IV as compared to more 
advanced stages in the non-BE/IM group 4.8%, 17.9%, 44.9% and 32.4% respectively (P<0.001) (Table 1). 
Tumor length was overall similar for both groups when matched for stages I-III (Supplementary Table 1).   
Nevertheless, at stages  I and IV and tumor lengths 3-6 cm and > 6 cm, respectively,  non-BE/IIM trended 
toward association with longer tumor  length.  Both groups were treated similarly with neoadjuvant 
chemoradiation therapy followed by esophagectomy (45.6% in the BE/IM and 44% in non-BE/IM). 
Patients in the non-BE/IM group were more likely to undergo radiation, and/or chemotherapy alone 79 
(38.2%) compared to 29 patients (14.2%) in the BE/IM group where there was a higher prevalence of 
stage IV disease. Endoscopic therapy was more common among the BE/IM group.  
  
OCCAMS Consortium 
28% of tumors (n=395) were in the distal esophagus (Siewert Type I), with 35% of these 
occurring in the BE/IM group. 35% (n=501) of tumors were classified as spanning the esophagogastric 
(Siewert Type II), with 33% (n=213) in the BE/IM group compared with 36% (n=288) in the non-BE/IM 
group. The majority of patients received neoadjuvant chemotherapy and esophagectomy (66%, n=934) 
with no difference between the two groups. The BE/IM group was more likely to receive esophagectomy 
only (22%, n=137) while the non-BE/IM patients were more likely to receive chemo and/or radiotherapy 
as the only treatment (9.7%, n=76). Most patients in the cohort were TNM stages II (47%, n=662) or III 
(34%, n=480). BE/IM was likely to be found in stage II patients (51%, n=323), while stage III patients 
were more often in the non-BE/IM group (36%, n=285). Patients with BE/IM tended to be more 
commonly associated with early stages (TNM I, 8.4%), however these accounted for only 5% (n=70) of all 
cases (Table 1).   
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Survival  
Mayo Clinic 
The median overall survival for the entire cohort was 4 years (IQR: 1.3-6.5). Among BE/IM 
patients, the median survival was 5.8 years (IQR: 2.5 – 7.2), compared to 2.3 years (IQR: 0.9 – 5.6) for 
the non-BE/IM group (P<0.001) (Figure 1). The 5-year mortality was 219/411 (53.3%) in the entire 
cohort. This was significantly lower in the BE/IM group 75/203 (36.8%) compared to the non-BE/IM 
144/207 (69.6%) in non-BE/IM, P<0.001.  
  Comparing overall survival, the unadjusted model demonstrated a significant survival benefit in 
the BE/IM group (hazard ratio (HR), 0.44; 95% confidence interval (CI), 0.34 – 0.57, P<0.001) (Figure 1). A 
multivariable Cox regression analysis including age at diagnosis, sex, tumor location and length and TNM 
stage resulted in an adjusted hazard ratio (aHR) of 0.66 (95% CI: 0.5–0.88, P=0.005) indicating better 
survival associated with BE/IM phenotype independent of the above factors.  
 
OCCAMS Consortium 
The median overall survival for the OCCAMS cohort was 1.6 years (IQR: 0.9-2.6). Among BE/IM 
patients the median survival was 3.4 years (IQR 2.9-4.4), compared to 2.0 years (IQR 1.9-2.3) for the 
non-BE/IM group (P<0.001). In the 864 patients that were diagnosed prior to 2014, 92% received 
curative treatment and the 5-year mortality was 444/864 (51%), with 42% (164/386) in the BE/IM 
patients and 58% (280/478) in non-BE/IM patients (P<0.001). When comparing overall survival, the 
unadjusted model demonstrated a significant difference between the two groups with a survival benefit 
in the BE/IM group (HR 0.58, 95% CI: 0.49-0.68, P<0.001) (Figure 1). A multivariable analysis including 
age at diagnosis, sex, tumor location, and TNM stage resulted in an aHR of 0.77 (95% CI: 0.64-0.93, 
P=0.006).  
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Subgroup analysis 
Mayo Clinic     
In a multivariable Cox proportional hazards regression that included age at diagnosis and sex for 
all the models, we performed predefined subgroup analyses to determine if the survival difference was 
influenced by location (Siewert classification), TNM stage or receiving neoadjuvant therapy. In patients 
with tumors classed as either Siewert I (n=226, HR=0.38, 95% CI: 0.27-0.54, P<0.001) or Siewert II 
(n=166, HR=0.5, 95% CI: 0.33-0.77, P=0.002) the BE/IM group showed better survival indicating that the 
effect of BE/IM is independent of esophageal location (Figure 2A).  
In a subgroup analysis for each TNM stage, there was a benefit for BE/IM patients in TNM stages 
II (n=92, HR=0.49, 95% CI: 0.27-0.87, P=0.01) and III (n=154, HR=0.6, 95% CI: 0.4-0.93, P=0.02) (Figure 
2B). There was no difference in survival between BE/IM and non-BE/IM in stage I (HR: 0.59, 95%CI: 0.2 – 
1.8, P=0.35) and IV (HR: 0.99, 95% CI: 0.6 – 1.6, P=0.97).  
In patients who underwent esophagectomy after neoadjuvant chemoradiation (n=184, HR=0.6, 
95% CI: 0.38-0.97) a better survival for BE/IM patients persisted (Figure 2C). The subgroup of patients 
receiving surgery without neoadjuvant therapy (n=50), the HR was consistent with other subgroups and 
suggests that the benefit of BE/IM persist (HR: 0.35, 95% CI: 0.14 – 0.86, P=0.02). Finally, we performed 
a subgroup analysis excluding patients who did not undergo surgical or endoscopic resection (i.e. 
chemo-radiation therapy alone or palliative therapy) to minimize the risk of tissue sampling error. BE/IM 
was associated with superior survival compared to non-BE/IM HR: 0.65 (95%: 0.44 – 0.96, P=0.03) 
adjusting for age, sex, tumor location and length and TNM stage.  
 
OCCAMS Consortium 
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In a multivariable Cox proportional hazards regression that included age at diagnosis and sex we 
performed subgroup analyses to determine if other factors could be driving the survival difference 
observed these patients.  Patients undergoing surveillance for Barrett’s, tumor location (i.e. Siewert 
classification), TNM stage,  tumor differentiation (i.e. poor, moderate, well), surgery with/without 
neoadjuvant chemotherapy, and response to chemotherapy (i.e. change in tumor stage pre- and post-
surgery), were all tested and had no effect (see Supplementary Figures 1-5).  
 We additionally assessed whether the effect of BE/IM depends on stage, and how strong the 
dependence is.  We added a random term for the BE/IM-TNM stage interaction to the model. The 
estimated variance for this term was 1.52x10
-5
, so the impact of TNM stage on the hazard ratio can be 
considered negligible.  
 Finally, we evaluated the impact of the missing data in each category by imputing the missing 
data points based on observed distributions, and assessing the multivariable Cox regression from the full 
dataset. We performed 20 iterations of the imputation and a consistent improvement to the aHR of 
BE/IM resulted (mean aHR=0.64 ± 0.008, P<0.001) indicating that the survival difference is robust to 
missing data. 
 
DISCUSSION 
In this study we have demonstrated the association between the presence of gross Barrett’s 
esophagus and/or histologic IM on EAC survival in two independent cohorts. In a retrospective, single 
center cohort from the USA we found that EAC on the background of BE/IM presented at earlier stages 
and had better survival even after adjusting for disease stage, tumor location and length, and 
neoadjuvant treatment. These findings were similar in the OCCAMS cohort, a larger cohort of patients 
with EAC collected from multiple hospitals in the UK.   
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While both cohorts demonstrated an improved survival when there was associated Barrett’s, 
there was a difference in median overall survival which was 1.3 years (IQR: 0.6-2.3) in the UK OCCAMS 
cohort versus the 4 years (IQR: 1.3-6.5) survival seen in the Mayo cohort. It is noteworthy that the UK 
data reflects the typical 5-year survival for EAC of 12-20%
20, 21
.  The Mayo clinic is a tertiary referral 
center and there was a higher proportion of early stage tumors (6% in OCCAMS vs 17% in Mayo) and the 
UK population was slightly older (66 ± 9.4 years for OCCAMS, 64.0 ± 10.7 for Mayo). Additionally, in both 
cohorts the survival benefit persisted with exclusion of neo-adjuvant therapy exposure to cancers with 
pre-existing BE/IM.  On the other hand, more aggressive use of neo-adjuvant therapy at Mayo may 
explain some of the overall improved survival differences as well 
22
. 
   A key question is what it means from an etiological perspective when Barrett’s and/or IM is not 
identified at the time of esophageal adenocarcinoma resection or diagnosis.  Several possibilities could 
be considered.  .  First, that IM was present but then eradicated by tumor growth and this scenario has 
been proposed previously 
23, 24
, however in the Mayo cohort a finding of BE/IM was overall similar for 
both groups within cancer stage I-III, independent of the length of the tumor making overgrowth of 
gross intestinal metaplasia by a larger tumor less likely  an explanation in the non-BE group.  On the 
other hand, in specific subgroups of stage and tumor length, there appeared to be differences 
supporting the possibility of tumor overgrowth in some patients.   Second, is that there is acquisition of 
sudden genomic instability that allows extant intestinal metaplasia to progress rapidly to cancer that is 
no longer visible in the tumor
25
. Investigations into molecular mechanisms including mutational 
signatures, copy-number differences, or recurrent gene mutation analyses that could explain these 
difference have so far been inconclusive. This is likely due to the complexity of the molecular profile of 
EAC26. Work is ongoing to examine the molecular characteristics in the subset of patients in the OCCAMS 
cohort with whole genome sequencing data.  Third, the cancer derives through a molecular sequence 
not involving IM27. 
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        While the initial study at the Mayo clinic was limited due to the use of specimens from a single 
center, the demographics of these patients are representative of the typical patient who develops EAC - 
middle to older age white man with increased BMI. This limitation has been addressed by the 
independent identification of similar findings in the OCCAMS cohort, which includes patients 
prospectively recruited from 25 different hospitals across the UK. A second concern may be the 
assuredness with which we propose the existence of these two types of cancer based only on finding 
BE/IM at diagnosis and/or resection, with the possibility of missing a small focus of IM. Systematic 
pathology review for the presence of IM could help mitigate this limitation, and the prospective 
OCCAMS cohort addressed this since the presence of BE/IM is systematically assessed in all patient 
samples as part of the study protocol. Furthermore, in a small subset of the OCCAMS patients an 
independent review of their pathological reports was undertaken, and the survival advantage remained 
for the BE/IM group.  
      One important finding that also argues for a different phenotype of esophageal cancer is that cancers 
without IM accounted for almost half the EACs from the years studied and were mostly distal EACs .  
This stands in contrast to data demonstrating that the majority of esophageal adenocarcinomas develop 
in a segment of Barrett’s mucosa
28
. As a result, this data further suggests the existence of a different 
phenotype of esophageal adenocarcinoma rather than misclassifying the IM type that would have more 
likely arisen in the presence of long segment Barrett’s mucosa. Another limitation might be in 
determining whether the poorer prognosis of EAC without IM results from poor response to therapy  
since most patients with stage II and III EAC receive chemotherapy, and in the USA radiation therapy.  
Given the inaccuracy of endoscopic ultrasound and PET/CT for assessing lymph node involvement and T 
stage before therapy, it would be difficult to compare response before and after treatment.   However, 
analysis of patients with stage II cancer not treated with neo-adjuvant therapy showed persistent 
survival benefit of Barrett’s/IM cancers when compared to non-BE/IM cancers, as did an analysis of 
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response based on the differences between pre- and post-resection tumor staging.    Furthermore, the 
advanced presentation of non-BE/IM adenocarcinoma before therapy suggests a more aggressive 
cancer.  Finally, another concern is whether we are confusing cancers of the esophago-gastric junction 
with similarly true esophageal adenocarcinoma which may carry a different molecular signature and 
prognosis. However, in both cohorts the survival advantage of BE/IM was present regardless of the 
location of the tumor. In our study, the patients without BE and distal adenocarcinoma extending to EGJ 
but not Siewert II adenocarcinoma had similar demographics to those with Barrett’s patients as all 
tumors extended > 1 cm above the gastroesophageal junction
17
. Furthermore, when we excluded all 
patients with extension of tumor into the cardia, there was a persistent decrease in overall survival 
when compared to Barrett’s/IM related tumors.   
        In conclusion, this study suggests that there are phenotypically two types of esophageal 
adenocarcinoma – one with grossly visible and/or histologically identifiable intestinal metaplasia in the 
esophagus and one without.  Furthermore, the presence or absence of these findings may influence the 
ability for early detection in this disease through screening for BE. It may also have ramifications for 
tumor behavior and/or response to therapy and therefore prognosis.  Longitudinal and detailed 
molecular characterization studies are required to shed further light on the natural history of EAC that 
presents de novo, in order to develop evidenced based screening and prevention strategies for this 
highly lethal malignancy on a population basis.   Finally, sequencing will be needed to determine 
ultimately if this new phenotype is an intestinal metaplasia independent pathway.   
 
Figures Legends: 
Figure1: Overall survival time in years comparing esophageal adenocarcinoma with and without BE/IM, 
(A):  Mayo Clinic (P<0.001), (B): OCCAMS (P<0.001) 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
19 
 
Figure 2: Forest plots for subgroup analysis HR in Mayo Clinic cohort for BE/IM vs non-BE/IM adjusting 
for age and sex including:  (A) location based on Siewert classification, (B) TNM stage, (C) Surgery 
with/without neoadjuvant therapy.  
 
Table 1: Baseline characteristics of included patients, comparing patients with identified BE/IM to those 
without BE/IM in the Mayo Clinic (A) and OCCAMS cohort (B). 
 
Table 2: Predictors for survival in EAC patients presented as hazard ratios from multivariable cox 
regression model including Barrett’s phenotype, sex, age at diagnosis, Siewert classification and 
TNM stage in both cohorts and tumor length in the Mayo cohort  
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Table 1: Baseline characteristics of included patients, comparing patients with identified BE/IM to those without BE/IM in the Mayo Clinic 
(A) and OCCAMS cohort (B) 
  (A) Mayo (B) OCCAMS 
  BE/IM, 
n=204 
Non-BE/IM, 
n=207 
P value Total, n=411 BE/IM 
n=634 
Non-BE/IM, 
n=783 
P value Total n=1417 
Age at diagnosis, 
mean years (SD) 
65 (10.4)  63 (11) 0.02 64 (10.7) 67 (9) 66 (9.8) 0.06   
Male, n (%) 172 (84) 178 (86) 0.6 350 (85.2) 539 (85) 640 (81.7) 0.1 1179 (83.2) 
BMI, mean (SD, 
IQR) 
29.4  
(5, 26-32) 
29  
(5.4, 25-33) 
0.6 29 (5.3, 25-32) 28 (5, 25-
31) 
27 (4.8, 24-29) < 0.001   
History or current 
Smoking, n (%) 
128 (63) 128 (62) 0.2 256 (62.3) 362 (57.1) 456 (58.2) 0.07 818 (57.7) 
Family history of 
EAC, n (%) 
9 (4.4) 11 (5.3) 0.6 20 (5) 39 (6.2) 39 (5) 0.662 78 (5.5) 
TNM Stage, n (%)     <0.001       < 0.001   
I 62 (30.4) 10 (4.8)   72 (17.5) 53 (8.4) 17 (2.2)  70 (4.9) 
II 55 (27) 37 (17.9)   92 (22.4) 323 (50.9) 339 (43.3)   662 (46.7) 
III 61 (29.9) 93 (44.9)   154 (37.5) 195 (30.8) 285 (36.4)  480 (33.9) 
IV 26 (12.7) 67 (32.4)   93 (22.6) 8 (1.3) 46 (5.9)  54 (3.8) 
Missing 0 0   0 55 (8.7) 96 (12.3)  151 (10.7) 
T stage, n (%)     <0.001       < 0.001   
T0 0 0   0 10 (1.6) 3 (0.4)  13 (0.9) 
T1 66 (32.4) 11 (5.3)   77 (18.7) 70 (11) 21 (2.7)  91 (6.4) 
T2 41 (20.1) 23 (11.1)   64 (15.6) 86 (13.6) 60 (7.7)  146 (10.3) 
T3 46 (37.3) 107 (51.7)   183 (44.5) 380 (59.9) 511 (65.3)  891 (62.9) 
T4 1 (0.5) 4 (1.9)   5 (1.2) 34 (5.4) 95 (12.1)  129 (9.1) 
Missing 20 (9.8) 62 (30)   82 (20) 52 (8.2) 93 (11.9)  145 (10.2) 
N stage, n (%)     <0.001       < 0.001   
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N0 89 (43.6) 32 (15.5)   121 (29.4) 155 (24.4) 146 (18.6)  301 (21.2) 
N1 77 (37.8) 84 (40.6)   161 (39.2) 205 (32.3) 230 (29.4)  435 (30.7) 
N2 12 (5.9) 20 (9.7)   32 (7.8) 139 (21.9) 190 (24.3)  329 (23.2) 
N3 5 (2.5) 8 (3.9)   13 (3.2) 76 (12) 139 (17.8)  215 (15.2) 
Missing 21 (10.3) 63 (30.4)   84 (20.4) 53 (8.4) 78 (10)  131 (9.2) 
Location (Siewert 
class), n (%) 
    0.8       < 0.001   
1 (Distal 1-5cm 
above EGJ) 
109 (53.4) 117 (56.5)   226 (55) 222 (35) 173 (22.1)  395 (27.9) 
2 (1cm above- 2cm 
below EGJ) 
86 (42.2) 80 (38.6)   166 (40.4) 213 (33.6) 288 (36.8)  501 (35.4) 
3 (2-5 cm below 
EGJ) 
-- --   -- 50 (7.9) 125 (16)  175 (12.4) 
Missing 4 (2) 6 (2.9)   10 (2.4) 149 (23.5) 197 (25.2)  346 (24.4) 
Tubular esophagus 
above 5 cm 
5 (2.4) 4 (2)   9 (2.2) -- --   -- 
Treatment, n (%)     <0.001       < 0.001   
Endoscopic 
therapy 
37 (18.1) 2 (1)   39 (9.5) -- --   -- 
Esophagectomy 
alone 
31 (15.2) 10 (4.8)   41 (9.9) 137 (21.6) 114 (14.6)  251 (17.7) 
Neoadjuvant 
chemotherapy & 
esophagectomy 
93 (45.6) 91 (44)   184 (44.8) 416 (65.6) 518 (66.2)  934 (65.9) 
Esophagectomy & 
adjuvant chemo-
radiation 
5 (2.4) 4 (1.9)   9 (2.2) -- --   -- 
Chemo and/or 
radiation therapy 
alone 
29 (14.2) 79 (38.2)   108 (26.3) 25 (3.9) 76 (9.7)  101 (7.1) 
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Palliative  4 (2) 17 (8.2)   21 (5.1) 13 (2.1) 76 (9.7)  89 (6.3) 
Missing 5 (2.4) 4 (1.9)   9 (2.2) -- --   -- 
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Table 2: Predictors for survival in EAC patients presented as hazard ratios from multivariate cox regression model 
including Barrett’s phenotype, sex, age at diagnosis, Siewert classification and TNM stage in both cohorts  and the 
tumor length in  the Mayo cohort 
  Mayo 
  OCCAMS    
  Total, N= 411
 
Adjusted 
HR
  
95% CI  Total, N= 1417  Adjusted HR  95% CI 
Barrett's Esophagus 
  
    
   
     
Non -BE/IM  207  Reference  __  783  Reference  
 
BE/IM
  204  0.66  0.5 -  0.88   634  0.77  0.64 - 0.93 
Sex
  
                
Male 350  Reference     1179  1.1  0.84 - 1.43 
Female 61
  1.02  0.72 - 1 .44  238  Reference  
 
Age at diagnosis 
(years)  
411  1.02  1.01 - 1.04  1417  1.01  1.0 - 1.02  
Siewert Classification  
                 
1
  226  Reference  __  395  Reference  
 
2
  166  0.75  0.56 -  1  501  0.85  0.7 - 10.5  
3
  0 __  __  175  0.92  0.7 - 1.2  
Tubular 
  9 1.24  0.56 -  2.74  __ __  __  
Missing 10
  1.88  0.9 –  3.95  
     
TNM stage  
                 
I 72
  Reference  __  70 Reference  
 
II 92
  2  1.2 2  -  3. 44  662  3.25  1.44 - 7.33 
III
  154  3  1.8 – 5.1 480  6.25  2.77 - 14.13  
IV 93
  6.9  4 - 11.9  54 10.02  4.14 - 24.23  
Missing 
  0 __  __          
Tumor length  
   
1-3 cm
 
161  Reference        
3 cm<Length ? 6 cm 
  129    0.82  0.57 -  1.18       
>6 cm 69
  1.1  0.7 -  1.63       
Missing 52
  1.1  0.68 -  1.7          
  Log- Rank P<0.001  Log - Rank P<0.001  
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Supplementary Figures 
 
In the OCCAMS cohort we test the following covariates to determine if these drive the survival difference 
for BE/IM patients: Barrett’s surveillance (Suppl. Fig. 1), tumor location (Suppl. Fig. 2), TNM Stage (Suppl. 
Fig. 3), treatment (Suppl. Fig. 4), and response to neoadjuvant therapy (Suppl. Fig. 5). All models control 
for age at diagnosis and sex. 
 
None of the subgroups alter the effect of BE/IM on survival. 
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Supplementary Figure 1:  Barrett’s surveillance in OCCAMS cohort 
 
 
 
 
 
 
Supplementary Figure 2: Siewert classification. 
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Supplementary Figure 3: TNM stages. 
 
 
 
 
 
Supplementary Figure 4: Treatment regimens. 
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Supplementary Figure 5: Tumor response to neoadjuvant therapy. 
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Supplementary Table 1. Tumor length comparison between BE/IM and non-BE/IM based on stages for the Mayo cohort  
 
 
Stage Length 1-3 cm 3 cm<Length ≤ 6 cm Length >6 cm Missing P 
value  
 BE/IM, n 
(%) 
Non-BE/IM, 
n (%) 
BE/IM, n 
(%) 
Non-BE/IM, 
n (%) 
BE/IM, n 
(%) 
Non-BE/IM, 
n (%) 
BE/IM, n 
(%) 
Non-
BE/IM, n 
(%) 
 
I 53 (85.5) 6 (60) 4 (6.5) 3 (30) 0 0 5 (8) 1 (10) 0.06 
II 31 (56.4) 17 (46) 17 (30.9) 12 (32.4) 4 (7.3) 3 (8.1) 3 (5.4) 5 (13.5) 0.54 
III 15 (24.6) 25 (26.9) 26 (42.6) 39 (41.9) 16 (26.2) 22 (23.7) 4 (6.6) 7 (7.5) 0.97 
IV 8 (30.8) 6 (9) 10 (38.5) 18 (26.9) 3 (11.5) 21(31.3) 5 (19.2) 22 (32.8) 0.01 
 
 
 
